Yanan Zhu
Stock Analyst at Wells Fargo
(4.60)
# 938
Out of 4,651 analysts
431
Total ratings
39.4%
Success rate
17.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Atrium Therapeutics | Maintained: Buy | $25 | $12.84 | +94.70% | 3 | Aug 14, 2026 | |
| PHVS Pharvaris | Rated: Buy | $55 | $35.14 | +56.52% | 2 | Aug 13, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.70 | +17.65% | 19 | Aug 12, 2026 | |
| MGX Metagenomi Therapeutics | Rated: Buy | $9 → $7 | $1.23 | +469.11% | 15 | Aug 11, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $18.10 | +109.94% | 16 | Aug 6, 2026 | |
| ONC BeOne Medicines AG | Maintained: Buy | $400 | $347.48 | +15.11% | 3 | Aug 6, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $75 | $53.55 | +40.06% | 16 | Aug 5, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $90 → $115 | $103.63 | +10.97% | 15 | Aug 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $100 → $95 | $57.24 | +65.97% | 45 | Jul 30, 2026 | |
| SGMOQ Sangamo Therapeutics, Inc. | Rated: Hold | n/a | $0.175 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 | $26.75 | +161.68% | 22 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $11.91 | +25.94% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $95 → $105 | $74.13 | +41.64% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.95 | +84.87% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $26.98 | +66.79% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.82 | +41.84% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $60 | $48.62 | +23.41% | 27 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $8.23 | +143.01% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $6.98 | +100.57% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.15 | +132.56% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.05 | +31.15% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 | $2.57 | -2.72% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1 | $0.029 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.27 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $34.91 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $45 → $30 | $1.93 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $272 → $326 | $851.29 | n/a | 4 | Feb 2, 2021 |
Atrium Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $25
Current: $12.84
Upside: +94.70%
Pharvaris
Aug 13, 2026
Rated: Buy
Price Target: $55
Current: $35.14
Upside: +56.52%
enGene Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $2
Current: $1.70
Upside: +17.65%
Metagenomi Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $9 → $7
Current: $1.23
Upside: +469.11%
Sarepta Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $38
Current: $18.10
Upside: +109.94%
BeOne Medicines AG
Aug 6, 2026
Maintained: Buy
Price Target: $400
Current: $347.48
Upside: +15.11%
CRISPR Therapeutics AG
Aug 5, 2026
Maintained: Hold
Price Target: $75
Current: $53.55
Upside: +40.06%
Spyre Therapeutics
Aug 4, 2026
Maintained: Buy
Price Target: $90 → $115
Current: $103.63
Upside: +10.97%
Ionis Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: $100 → $95
Current: $57.24
Upside: +65.97%
Sangamo Therapeutics, Inc.
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.175
Upside: -
Jun 4, 2026
Maintained: Buy
Price Target: $70
Current: $26.75
Upside: +161.68%
May 12, 2026
Maintained: Hold
Price Target: $15
Current: $11.91
Upside: +25.94%
May 7, 2026
Maintained: Buy
Price Target: $95 → $105
Current: $74.13
Upside: +41.64%
May 7, 2026
Maintained: Buy
Price Target: $11
Current: $5.95
Upside: +84.87%
Apr 2, 2026
Maintained: Buy
Price Target: $45
Current: $26.98
Upside: +66.79%
Mar 10, 2026
Maintained: Hold
Price Target: $4
Current: $2.82
Upside: +41.84%
Mar 9, 2026
Upgraded: Buy
Price Target: $15 → $60
Current: $48.62
Upside: +23.41%
Mar 4, 2026
Maintained: Buy
Price Target: $20
Current: $8.23
Upside: +143.01%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $6.98
Upside: +100.57%
Jan 14, 2026
Maintained: Buy
Price Target: $5
Current: $2.15
Upside: +132.56%
Jan 13, 2026
Maintained: Hold
Price Target: $4
Current: $3.05
Upside: +31.15%
Jan 5, 2026
Maintained: Hold
Price Target: $2.5
Current: $2.57
Upside: -2.72%
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $1.5 → $1
Current: $0.029
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $10
Current: $3.27
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $34.91
Upside: n/a
Aug 16, 2023
Maintained: Hold
Price Target: $45 → $30
Current: $1.93
Upside: n/a
Feb 2, 2021
Maintained: Hold
Price Target: $272 → $326
Current: $851.29
Upside: n/a